Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study.

Objective: The purpose of this study was to assess the efficacy of buccal misoprostol to decrease uterine atony, hemorrhage, and the need for additional uterotonic agents during cesarean delivery.

Study Design: Patients who underwent cesarean delivery were assigned randomly to either 200-microg misoprostol or placebo placed in the buccal space. A dilute intravenous oxytocin infusion was given to all patients at delivery of the placenta.

Buccal misoprostol to decrease blood loss after vaginal delivery: a randomized trial.

Objective: To assess the efficacy of buccal misoprostol to decrease bleeding after vaginal delivery.

Methods: This was a randomized study of patients between 22 weeks and 42 weeks of gestation with anticipated vaginal delivery. Patients were given either a 200-mug misoprostol tablet or placebo in the buccal space at the time of cord clamping.

Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial.

Objective: To compare oral rofecoxib with intravenous magnesium sulfate as a tocolytic.

Methods: This was a randomized study of patients who were between 22 and 34 weeks of gestation with preterm labor. Patients were randomly assigned to receive either daily oral rofecoxib (50 mg) or intravenous magnesium sulfate for a maximum of 48 hours.